Luxana Biotech is a preclinical antisense oligonucleotide (ASO) development company based on proprietary nucleic acids with unique cross-linking structures. We have created the LuxiAP™ ASO drug discovery platform for the central nervous system and ophthalmic fields. The company has collaborative research agreements with multiple pharmaceutical companies and maintains its own ASO pipeline. We are seeking to expand partnership opportunities not only for collaborative research with pharmaceutical companies but also for joint development utilizing our proprietary pipeline.
ルクサナバイオテク株式会社と住商ファーマインターナショナル株式会社によるルクサナバイオテクの人工修飾核酸アミダイトの製造販売に係るライセンスの契約を締結しましたのでお知らせします。 [画像: https://p...
[画像: https://prtimes.jp/i/49692/13/resize/d49692-13-40a38d37771416c2edb6-0.png ] 製薬会社・化学会社と協働し、有望な人工核酸を活用した核酸医薬創薬を目指すルクサナバイオテク株式会社（本社：大阪府...
[画像: https://prtimes.jp/i/49692/9/resize/d49692-9-51a392b4d1239b861316-0.png ]   ルクサナバイオテク株式会社（代表取締役社長CEO：佐藤秀昭、本社：大阪府吹田市、以下「ルクサナバイ...
[画像: https://prtimes.jp/i/49692/8/resize/d49692-8-540686c9ee246c06666b-0.png ] ルクサナバイオテク株式会社（代表取締役社長：佐藤秀昭、本社：大阪府吹田市、以下「ルクサナバイオテク」）は、武田薬...
  [画像: https://prtimes.jp/i/49692/6/resize/d49692-6-73d0358b1bc375d57266-0.png ] 新規人工核酸を駆使し有効性と安全性の高い核酸医薬品を開発するルクサナバイオテク株式会社（本社：大阪府吹...
[画像: https://prtimes.jp/i/49692/5/resize/d49692-5-fdbb342ebd6451f9a275-0.png ] ルクサナバイオテク株式会社（代表取締役 佐藤 秀昭、本社：大阪府、以下「ルクサナバイオテク」）は、2018 年 12 月に Al...
[画像: https://prtimes.jp/i/49692/4/resize/d49692-4-254796-0.png ] ルクサナバイオテク株式会社（本社：大阪府吹田市、代表取締役社長：佐藤 秀昭、以下「ルクサナバイオテク」）は、大日本住友製薬株...
[画像: https://prtimes.jp/i/49692/3/resize/d49692-3-360475-0.png ]     安全性と有効性の高い新規核酸医薬品を開発するルクサナバイオテク株式会社（本社：大阪府吹田市、代表取締役社長...
ルクサナバイオテク株式会社（本社：大阪府吹田市、代表取締役社長：佐藤 秀昭、以下「ルクサナバイオテク」）と学校法人愛知医科大学（本学：愛知県長久手市、以下「愛知医科大」）は、国立研究開発法人日本...
A startup developing mass-producible platelet preparations using technology to generate platelets from human iPS cells. It aims to provide stable supplies to medical settings in developed and developing countries facing blood donation shortages, thereby supporting transfusion medicine.
It is well established that drivers’ spatial cognitive abilities are closely linked to traffic accident risk. Our company is committed to advancing driver safety and extending driver retirement age by leveraging proprietary technologies that enable the quantitative assessment and targeted training of spatial cognition ability.
At Beef Sommelier, we provide our B-som Diagnosis with the aim of creating a world where producers can raise their ideal cattle and consumers can enjoy beef that truly matches their preferences. Our technology not only quantifies biological information from beef cattle, but also supports producers in achieving their target meat quality. By introducing a new scientific perspective that goes beyond conventional standards, we make the “unseen qualities” of beef visible and measurable. This enables consumers to clearly understand the characteristics of the beef they choose. B-som is the world’s first scientific diagnostic service that bridges the gap between producers and consumers.
A startup developing allogeneic T-cell therapies from pluripotent stem cells to provide novel treatments for advanced and recurrent cancers and immune-related diseases. Aiming to deliver the potential for a cure to diseases that were previously difficult to treat.